Financhill
Sell
3

MTVA Quote, Financials, Valuation and Earnings

Last price:
$0.73
Seasonality move :
-16.87%
Day range:
$0.71 - $0.87
52-week range:
$0.71 - $5.30
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.80x
Volume:
1.3M
Avg. volume:
887.2K
1-year change:
-78.4%
Market cap:
$6.4M
Revenue:
--
EPS (TTM):
-$4.04

Analysts' Opinion

  • Consensus Rating
    MetaVia has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
  • Price Target Upside
    According to analysts' consensus price target of $15.50, MetaVia has an estimated upside of 2010.85% from its current price of $0.73.
  • Price Target Downside
    According to analysts, the lowest downside price target is $6.00 representing -717.11% downside risk from its current price of $0.73.

Fair Value

  • According to the consensus of 1 analyst, MetaVia has 2010.85% upside to fair value with a price target of $15.50 per share.

MTVA vs. S&P 500

  • Over the past 5 trading days, MetaVia has underperformed the S&P 500 by -45.91% suggesting its relative strength compared to the major market average is weak at this time.

Share Buyback

  • MetaVia does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • MetaVia has grown year-over-year revenues for 0 quarters straight. In the most recent quarter MetaVia reported revenues of --.

Earnings Growth

  • MetaVia has grown year-over-year earnings for 0 quarters straight. In the most recent quarter MetaVia reported earnings per share of -$0.32.
Enterprise value:
-9.7M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
0.39x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
Trailing 12 Months Fiscal Quarters
Period Ending 2022-12-31 2023-12-31 2024-12-31 2023-12-31 2024-12-31
Income Statement
Revenue -- -- -- -- --
Gross Profit -- -- -- -- --
Operating Income -$11.4M -$15.9M -$28.8M -$5.7M -$5.6M
EBITDA -$11.8M -$15.9M -$28.8M -$5.7M -$5.6M
Diluted EPS -$85.15 -$2.46 -$4.04 -$1.05 -$0.32
Period Ending 2020-12-31 2021-12-31 2022-12-31 2023-12-31 2024-12-31
Balance Sheet
Current Assets $10.7M $16.6M $33.5M $22.5M $16.1M
Total Assets $11M $16.8M $33.5M $22.8M $16.3M
Current Liabilities $3.7M $2.2M $11.8M $6M $8.3M
Total Liabilities $3.8M $2.2M $11.8M $6.1M $8.3M
Total Equity $7.2M $14.6M $21.8M $16.7M $7.9M
Total Debt -- -- -- -- --
Trailing 12 Months Fiscal Quarters
Period Ending 2022-12-31 2023-12-31 2024-12-31 2023-12-31 2024-12-31
Cash Flow Statement
Cash Flow Operations -$11.7M -$10.8M -$24.7M -$3.4M -$5.4M
Cash From Investing $8K -$50K -$8K -$9K --
Cash From Financing $28.7M -$80K $18.3M -- -$224K
Free Cash Flow -$11.7M -$10.8M -$24.7M -$3.4M -$5.4M
MTVA
Sector
Market Cap
$6.4M
$35M
Price % of 52-Week High
13.86%
41.88%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.91%
1-Year Price Total Return
-78.4%
-43.29%
Beta (5-Year)
0.217
0.743
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

Technicals

8-day SMA
Sell
Level $1.29
200-day SMA
Sell
Level $2.63
Bollinger Bands (100)
Sell
Level 1.45 - 2.17
Chaikin Money Flow
Sell
Level -4.3M
20-day SMA
Sell
Level $1.45
Relative Strength Index (RSI14)
Sell
Level 28.73
ADX Line
Sell
Level 14.33
Williams %R
Buy
Level -98.2518
50-day SMA
Sell
Level $1.53
MACD (12, 26)
Sell
Level -0.12
25-day Aroon Oscillator
Sell
Level -4
On Balance Volume
Neutral
Level 51.3M

Financial Scores

--
Altman Z-Score (Annual)
Level (--)
--
CA Score (Annual)
Level (--)
--
Beneish M-Score (Annual)
Level (--)
Sell
Momentum Score
Level (1)
--
Ohlson Score
Level (--)
--
Piotroski F Score (Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)

Revenue Forecast

Earnings per Share Forecast

Company Profile

MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist for the treatment of obesity that is designed to be administered once weekly subcutaneously.

Stock Forecast FAQ

In the current month, MTVA has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The MTVA average analyst price target in the past 3 months is $15.50.

  • Where Will MetaVia Stock Be In 1 Year?

    According to analysts, the consensus estimate is that MetaVia share price will rise to $15.50 per share over the next 12 months.

  • What Do Analysts Say About MetaVia?

    Analysts are divided on their view about MetaVia share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that MetaVia is a Sell and believe this share price will drop from its current level to $6.00.

  • What Is MetaVia's Price Target?

    The price target for MetaVia over the next 1-year time period is forecast to be $15.50 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.

  • Is MTVA A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for MetaVia is a Buy. 1 of 1 analysts rates the stock a Buy at this time.

  • How Can I Buy Shares Of MTVA?

    You can purchase shares of MetaVia via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase MetaVia shares.

  • What Is The MetaVia Share Price Today?

    MetaVia was last trading at $0.73 per share. This represents the most recent stock quote for MetaVia. Yesterday, MetaVia closed at $0.73 per share.

  • How To Buy MetaVia Stock Online?

    In order to purchase MetaVia stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Micron a Good Stock to Buy Now?
Is Micron a Good Stock to Buy Now?

Like most of its peers in the semiconductor industry, Micron…

Is Uber Finally on the Path to Consistent Profitability?
Is Uber Finally on the Path to Consistent Profitability?

After posting massive losses quarter after quarter for years, Uber…

How High Will MSTY Go By 2030?
How High Will MSTY Go By 2030?

YieldMax’s MSTR Option Income Strategy ETF (MSTY) is a high-yield…

Stock Ideas

Sell
48
Is AAPL Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 32x

Sell
46
Is MSFT Stock a Buy?

Market Cap: $2.8T
P/E Ratio: 31x

Sell
42
Is NVDA Stock a Buy?

Market Cap: $2.5T
P/E Ratio: 36x

Alerts

Sell
25
BULZ alert for Apr 17

MicroSectors Solactive FANG & Innov 3X Levd ETN [BULZ] is down 10.95% over the past day.

Sell
50
IBKR alert for Apr 17

Interactive Brokers Group [IBKR] is down 8.97% over the past day.

Sell
39
FNGA alert for Apr 17

MicroSectors FANG+ Index 3X Leveraged ETN [FNGA] is down 9.37% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock